ARD-2051

ARD-2051

• CAS Number: 2632305-17-8
• UNSPSC Description: ARD-2051 is a potent and orally active androgen receptor (AR) proteolysis-targeting chimera degrader. ARD-2051 achieves DC50 values of 0.6 nM for AR protein degradation in both the LNCaP and VCaP prostate cancer cell lines. ARD-2051 can be used for the research of prostate cancer[1].
• Target Antigen: Androgen Receptor; PROTACs
• Type: Reference compound
• Related Pathways: PROTAC;Vitamin D Related/Nuclear Receptor
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/ard-2051.html
• Solubility: DMSO : 25 mg/mL (ultrasonic)
• Smiles: O=C(C1=C2C=CC(N3CC(N4CCN(C(C5=CC=C(C=C5)N6CCC7(CC6)CN([C@H](C7)C)C8=CC(Cl)=C(C=C8)C#N)=O)CC4)C3)=C1)N(C2=O)C9C(NC(CC9)=O)=O
• Molecular Weight: 789.32
• References & Citations: [1]Han X, et al. Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer. J Med Chem. 2023 Jul 13;66(13):8822-8843.
• Shipping Conditions: Room Temperature
• Clinical Information: No Development Reported